**Noncoding RNA 886 alleviates tumor cellular immunological rejection in host C57BL/C mice**

Hui Ma¹ | Miao Wang² | Ying Zhou¹ | Jia-jie Yang¹ | Li-Yong Wang³ | Rong-hui Yang¹ | Min-jie Wen¹ | Lu Kong¹

¹Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing, China
²Department of Pathology, Beijing Friendship Hospital, The Second Clinical Medical College of Capital Medical University, Beijing, China
³Core Facilities for Molecular Biology, Capital Medical University, Beijing, PR China

**Abstract**

Non-coding RNA 886 (nc886/VTRNA2-1) is a Pol III transcript and an atypical imprinted gene. Its exact function as a negative regulator of protein kinase R establishes its connection with innate immunity. Studies have shown that nc886 silencing is closely associated with prostate cancer progression. Previous work has constructed a cell model of stable nc886 overexpression (“mimic” or “nc886+”) in PC-3M-1E8 cell lines (1E8), which are highly bone-metastatic human prostate cancer cells with low expression of nc886, and cells expressing the mimic were validated to have lower invasive and metastatic abilities than cells expressing the scramble transcript in vitro and in vivo. In this study, we directly injected mimic or scramble cells into the left ventricle of C57BL/C mice, an immunocompetent animal model, to elucidate the immune mechanisms of tumor-host interactions. Interestingly, we found that tumor cells induced the inflammation of many important organs due to xenogeneic antigen rejection; this inflammation was ultimately repaired by tissue fibrosis after 28 days, except for in the spleen. The reason is that mimic cells, as heterogeneous antigens, are mostly directly recognized by macrophages or T cells in blood, and few mimic cells enter the spleen compared with scramble cells. The induction of splenic macrophage polarization to M2 macrophages by scramble cells is a critical factor in maintaining chronic splenic inflammation. In addition, we recognize that nc886 broadly decreases the expression of some human leukocyte antigen molecules and antigen transporters. This evidence reveals the interesting role of nc886 in regulating tumor cell antigens.

**KEYWORDS**
cancer biology, epigenetics, immunology, metastasis, prostate cancer
INTRODUCTION

nc886, as a “metastable epiallele”, is a maternally methylated gene in humans. However, this gene is lost in mice or rats. Its aberrant methylation is closely associated with various cancers. In human prostate cancer, nc886 is considered as a tumor suppressor. Earlier studies reported that nc886 regulated PKR and 2',5'-oligoadenylate synthetase 1. King et al found that nc886 was a marker of T cell activation and that its transcriptional activation depended on IFN-γ and IL-12 produced by activated macrophages under conditions of viral infection. Accidentally, we noticed that nc886 alleviated the inflammatory response of acute rejection caused by human-derived prostate cancer cellular xenografts in immunocompetent mouse models. Hence, this study focuses on the immunomodulatory role of nc886 in prostate cancer cell lines. A few studies have reported the mechanism of the tumor cell-mediated immune response.

Cancer immunoediting research in immunodeficient hosts is obviously insufficient. However, even tumor cells from allogeneic or xenogeneic backgrounds can be rejected by immunocompetent host animals due to major histocompatibility complex (MHC) gene mismatches. MHC antigens and human leukocyte antigens (HLAs) are the most important known targets of the rejection response. More than 200 genes of the HLA complex are clustered on chromosome 6 and divided into three types: type I (HLA-A, -B, and -C), type II (HLA-DP, -DQ, and -DR), and type III (complement components, tumor necrosis factor, heat shock protein 70, and MHC class I-related chain A, B). Antigen presentation in antigen presenting cells (APCs) often requires the help of some antigen processing genes that are localized between the HLA class I and II genes, such as the TAP1, TAP2, LMP2, LMP7, DMA, and DMB genes. In addition, damage-associated molecular patterns (DAMPs) produced from dying cells have been recently identified as triggers of xenograft rejection.

To date, the best-known DAMPs include high-mobility group box-1 (HMGB1), S100A8 and S100A9 (calgranulin A and B), and serum amyloid A (SAA).

Inflammation induced by rejection is a complex immune process involving adaptive and innate immunity. Undoubtedly, macrophages are the main cells that mediate acute rejection within 1-2 days, and the M2 phenotype was recently shown to be the predominant phenotype in xenogeneic rejection. The polarization of macrophages is tremendously plastic, and their phenotype status generally depends on local environmental molecules. M1-type macrophages are frequently classified as activated macrophages and M2 as alternatively activated macrophages. In general, M1 macrophages are involved in killing bacteria, fungi, and viruses via the secretion of IL-1, IL-6, TNF-α, and IL-23, and M2 macrophages repair injured tissue by increasing the expression of arginase-1 (Arg-1), mannose receptor (CD206), IL-10, and transforming growth factor β (TGF-β). Additionally, M2 macrophages in the tumor microenvironment, considered tumor-associated macrophages (TAMs), have an immunosuppressive role that promotes tumor metastasis. Allograft rejection within 1-2 weeks primarily is a result of CD8+ cytotoxic T cells activated by type I alloantigens, which assist CD4+ helper T cells in recognizing type II alloantigens. The CD8-MHC I system can mediate early cellular rejection though direct T cell allorecognition. The CD4-MHC II system recognizes processed alloantigens on the surface of APCs and may be important in maintaining chronic rejection. Growing evidence has shown that xenogeneic antigens can also initiate T-cell-mediated direct or indirect rejection.

HLA molecules are highly polymorphic, and HLA-A, HLA-B, and HLA-DRB1 are recognized to be closely related to allogeneic rejection. Interestingly, our RNA-sequencing data analysis found that nc886 downregulated the expression of some mRNAs, including HLA-A, HLA-DRB1, and TAP1, in human prostate cancer cell lines. However, in humans, MHC I/II loss or downregulation on tumor cells often contributes to immune escape, metastatic progression and a poor prognosis in numerous malignancies. This discovery contradicted our understanding of the decreased invasive and metastatic abilities seen in mimic cells. Of course, focusing on one aspect at a time makes it hard to understand the overall picture. Some striking research has reported that xenogeneic rejection and cancer immunity might share a common molecular mechanism in the processes of induced necrosis and inflammation. Therefore, we further investigated this cross molecular mechanism in a model of immune rejection.

MATERIALS AND METHODS

2.1 Cell culture

1E8 cell lines were obtained from the Peking University Pathology Centre (Beijing, China) and were authenticated and checked for mycoplasma before experiments. Stable nc886-overexpressing 1E8 cells or control cells were established as described previously and labeled with GFP. Cell fluorescence imaging and QRT-PCR analyses were employed for verification.

2.2 Mice and immunohistochemistry

Our experimental aim was to investigate the mechanism by which tumor cells modulate immunity during blood metastasis. Hence, we built a blood metastatic model by injecting scorable or mimic 1E8 cells into the right atrium of mice (n = 12, 6 each group) after anesthesia. Animals were handled according to the guidelines and protocols supported by the Animal
Care and Use Committees (supplementary animal ethnic). The important tissues of these mice were fixed with 4% paraformaldehyde for histological examination or immunohistochemistry. Hematoxylin-eosin (H&E) staining was performed by a series of steps, including gradient dehydration, xylene clearing, wax embedding, dewaxing, and staining. For immunohistochemistry, tissue sections were routinely dewaxed, subjected to antigen retrieval and hydrogen peroxide incubation, blocked with goat serum for 0.5 hours, and incubated with the primary antibody overnight at 4°C. The primary antibodies were as follows: CD68 mouse monoclonal antibody (66231-2-Ig, Proteintech, 1:2000) and PSAT1 polyclonal antibody (A14124, ABclonal, 1:500). The secondary antibody (enzyme-labeled goat anti-mouse/rabbit IgG polymer, PV-6000, ZSGB-BIO) was incubated the next day for 0.5 hours. Finally, DAB substrate (ZLI-9017, ZSGB-BIO) was added to the sections for chromogenic analysis. The pathologic results were judged by an experienced pathologist.

2.3 | Bone marrow (BM) isolates and macrophage counting

DMEM containing 10% fetal bovine serum was injected into the femur and tibia of C57BL/6 mice, and then BM cells were suspended and cultured at 37°C overnight. The next day, unattached cells were discarded by changing the media. Cell morphology was photographed under an inverted fluorescence microscope (T1-SAM Nikon). Macrophage growth was evaluated by an EnoGeneCell™ Counting Kit-8 (CCK-8) (E1CK-000208, EnoGene).

2.4 | Transmission electron microscope (TEM)

Spleen tissue (1 mm³ sections) were routinely anterior-fixed in Karnovsky’s solution for 24 hours at 4°C, washed three times for 10 minutes in 0.1 mol/L phosphate buffer (PB), posteriorly fixed in 1% osmium acid for 1.5 hours, and then washed three times with 0.1 MPB buffer for 10 minutes each time. Then, solutions of 50%, 70%, 80%, and 90% ethanol were used to dehydrate the tissue for 15 minutes each. Samples were embedded with pure resin embedding agent and polymerized as follows: 35°C for 16 hours, 45°C for 8 hours, 55°C for 14 hours, and 60°C for 48 hours. Electronic staining was performed with uranium acetate for 30 minutes, followed by washing with pure water three times, lead citrate staining for 2 minutes, NaOH washing once, and pure water washing twice. Thereafter, dehydration, embedding, solidification, slicing, staining, and filming were performed using a transmission electron microscope. Observations were made with a JEM-1400 Plus electron microscope (Japan Electronics), and photographs were taken.

2.5 | RNA extraction, QRT-PCR and transcriptome sequencing

Total RNA extraction was performed according to the standardized process of the manufacturers’ instructions. We adopted standard kits, such as the TRIzol kit (Invitrogen), FastKing gDNA Dispelling RT SuperMix kit (KR118-02 TIANGEN) and PowerUp™ SYBR™ Green Master Mix (A25742, Applied Biosystems). All QRT-PCR primer sequences are found in Table S1.

The transcriptome experiments were managed by OE Biotech Co., Ltd. RNA sequencing was performed on three replicates. After RNA inspection using the Agilent 2100 Bioanalyzer (Agilent Technologies), the libraries were built using the TruSeq Stranded mRNA LT Sample Prep Kit (Illumina) and sequenced on the HiSeqTM 2500 sequencing platform. A total of 125 bp/150 bp paired-end reads were generated. The Genome Browser build hg19 was used for read alignment. A P value < .05 and a fold change (FC) >2 or <0.5 were set as the thresholds for differentially expressed genes. GO enrichment and KEGG pathway analyses of DEGs were performed using R software based on the hypergeometric distribution. Datasets were deposited in the Gene Expression Omnibus under accession no. GSE143451.

2.6 | Flow cytometry

Immune cells from animal tissue or blood were separated by using HISTOPAQ®-1077(10771, Sigma), and then the dissociated lymphocytes were resuspended in PBS and stained for surface markers for 20 minutes with antibodies: PerCP-CyTM 5.5 rat anti-mouse CD45 (550994, BD Biosciences, 1:200), FITC rat anti-mouse CD8a (553030, BD Biosciences, 1:500), APC rat anti-mouse CD11b (553312, BD Biosciences, 1:200), PE rat anti-mouse F4/80 (565410, BD Biosciences, 1:200), APC mouse anti-human HLA-ABC (555555, BD Biosciences, 1:200), APC mouse anti-human HLA-DR (560896, BD Biosciences, 1:125), and BV421 rat anti-mouse CD119 (740032, BD Biosciences, 1:200). Flow cytometry data were obtained on an LSRFortessa, and data analysis was achieved through FlowJo software (Tree Star).

2.7 | RNA immunoprecipitation (RIP) assay

All RIP experiments were carried out according to the instructions included with the RIP-Assay Kit (No. RN1001, MBL). Anti-MHC I (15240-AP, Proteintech) or TAP1 (11114-1-AP, Proteintech) antibodies were used to pull down endogenous nc886 complexes in mimic cells.
Cells were fixed with 4 mL of 1% formaldehyde at 37°C for 10 minutes. After washing three times with cold PBS, the cell precipitate was lysed with lysis buffer containing 60 μL of 50× protease inhibitor and rotated at 4°C for 30 minutes. Short DNA fragments (100-500 bp) were acquired using sonification under the following conditions: cycles: 99 times; continuous: 30 seconds; interval time: 30 seconds. Then, 100 μL of input was preserved. Four micrograms of antibody (anti-TAP1, anti-MHC I, or negative control IgG) and 30 μL of protein A/G magnetic beads were added to 250 μL of sonicated lysate and rotated at 4°C overnight. Finally, purified DNA/RNA was obtained by de-crosslinking and digesting the proteins with proteinase K. QRT-PCR was used to quantitatively evaluate the expression level of nc886.}

### 2.8 Western blot analysis

After quantification of protein concentration using a BCA assay (Pierce), proteins were separated by SDS-PAGE, transferred onto a PVDF membrane and then identified by immunoblot analysis with the appropriate primary antibodies at the following dilutions: anti-MHCI (15240-AP, Proteintech, 1:500) and anti-TAP1 (11114-1-AP, Proteintech, 1:500). GAPDH (#4967, 1:8000) was used as an internal control. HRP + goat anti-mouse IgG(H + L) (RS0001, ImmunoWay, 1:10 000) or anti-mouse IgG (sc-516102) was diluted to 1:8000. The membranes were developed using an enhanced chemiluminescence HRP substrate (WBKLS0500, Millipore Corporation Billerica) and then exposed to a MiniChemi 610 Imager (304002L, China).

### 2.9 Dual-luciferase reporter assays

Cells were seeded in 24-well plates, and plasmid transfection was performed the following day. Dual-luciferase activity was analysed with a Dual-Luciferase Reporter Assay System (E2920, Promega) in a microplate spectrophotometer (TriStar2 LB 942 Multimode Reader Berthold Technologies) according to the manufacturer's instructions.

### 3.1 Differentially downregulated genes between mimic and scramble cells were preferentially enriched in the immune system by transcriptome analysis

We checked differences of gene expression between the scramble and mimic cell lines by RNA sequencing analysis, and identified 2222 upregulated and 1546 downregulated differentially expressed genes (DEGs, P-value adjustment < .05, and fold change > 2) in mimic vs scramble cells and performed an analysis of associated biological processes, cellular components, and molecular functions (Figure S1). An important mode of ncRNA regulation is reduced expression of mRNA targets; as such, we focused on the 1546 downregulated genes. Interestingly, these differentially downregulated genes were preferentially enriched in processes related to the immune system, infectious disease, cancer, and signal transduction by GO analysis (Figure 1A, left). Additionally, the DEGs were found to be associated with signaling pathways related to the endoplasmic reticulum network by KEGG analysis (Figure1A, right). We specifically analysed all the HLA molecules, antigen transporters, costimulatory factors, DAMPs, and molecules related to the endoplasmic reticulum network from the sequencing data and found that nc886 significantly inhibited two HLA molecules (Figure 1B), four transporters, and two endoplasmic reticulum-related molecules (Figure1C). Of the HLA molecules, only HLA-A and HLA-DRB had mRNA levels that were significantly downregulated (2.12-fold and 2.28-fold, respectively) (Figure 1B), and TAP2, LMP-2, LMP-7, and HSP70, but not TAP1 and HSP90, were the transporter molecules that were significantly downregulated (2.12-fold, 2.27-fold, 2.50-fold, and 2.56-fold, respectively) in the nc886+ vs scramble groups (Figure 1C). Calnexin, Cathepsin and VTI1A (vesicle transport through interaction with t-SNAREs 1A) were significantly upregulated (2.12-fold and downregulated (2.81-fold and 2.13-fold) respectively. We validated these DEGs by QRT-PCR. The expression patterns of most DEGs were consistent with the expression patterns suggested by RNA sequencing except for those of TAP2, LMP-2, LMP-7, HSP70, and VTI1A (Figure 1D,E). TAP1 was validated to be approximately 10-fold downregulated in scramble cells vs mimic cells (Figure 1E). Presumably, nc886 might disturb the antigen presentation of HLA-A or HLA-DRB1 directly through transporter molecules in 1E8 cells.

### 3.2 Nc886 directly downregulates TAP1 and MHC-I expression in tumor cell line

We detected that the UTR regions of TAP1 and HLA-A were complementary sequences to the “seed” sequence of nc886.
endocytosis-related molecules (C) were statistically analysed. D,E, Validation of DEGs by QRT-PCR. Three independent experiments were performed

through the Needleman-Wunsch algorithm for global alignments, although the matches were imperfect (Figure S2). Next, we validated that the protein level of TAP1 was 2.1-fold downregulated and the protein level of MHC-1 was 1.56-fold downregulated in scramble cells vs mimic cells (Figure 2A, left). We examined whether nc886 directly downregulated TAPI and MHC-1 expression by luciferase reporter and ChIP experiments. We created constructs containing exons 1 or 8 of TAPI and HLA-A recombinants and their mutants and transfected them into scramble cells without nc886 expression or mimic cells with positive expression of nc886. The results showed that the luciferase value was reduced by approximately 4-fold in cells that had been transduced with TAPI vs mutant constructs in the mimic cell line after 24 hours of transfection; however, there was no significant difference in cells transduced with HLA-A vs mutant

FIGURE 1 Transcriptome sequencing analysis of the differentially expressed genes between scramble and nc886+ cells. A, Left, KEGG pathway classification for differentially downregulated genes in nc886+ vs scramble cells, showing that the genes were mainly enriched in processes related to the immune system. Right, KEGG enrichment of the top 20 of the total DEGs, showing that the genes were mainly clustered in the endocytosis pathway. Differential transcripts from HLA molecules (B), antigen transporters, costimulatory molecules, DAMP-related molecules, and endocytosis-related molecules (C) were statistically analysed. D,E, Validation of DEGs by QRT-PCR. Three independent experiments were performed.
constructs, and there was no change in scramble cell lines due to the lack of nc886 (Figure 2A, right). Consistent with these results, we successfully amplified the nc886 fragment in complex with TAP1 and MHC-1 by CHIP experiments (Figure 2B), suggesting that they should be direct target molecules of nc886. The combined findings of the two experiments showed that nc886 more directly downregulated TAP1 than HLA-A. Apparently, nc886 can directly alter the processing and presentation of intrinsic antigens including tumor antigen in tumor cells, which raises the question of what kind of immune response occurs when such tumor cells are injected to immunocompetent mice (Figure 2C)?

**FIGURE 2** Nc886 directly targets TAP1. A, Western blot analysis of TAP1, HLA-A and β-actin in scramble and nc886+ cells. The gray scale ratio (normalized to β-actin) was calculated by ImageJ software (left). TAP1 5’UTR and HLA-A 3’UTR plasmids were constructed and transfected into scramble cells or nc886+ cells. Dual-luciferase reporter assays were used to detect direct interactions with nc886 (right). B, The RIP experiment validated the interaction between nc886 and TAP1 or HLA-A in nc886+ cell lines, and the left picture verified that the magnetic beads were successfully loaded with antibodies. C, Schematic diagram and problem of nc886 changing tumor antigen.
MA et al.

3.3 | Nc886 alleviates immune rejection from injection of tumor cells into the left ventricle of C57BL/C mice

Using immunodeficient mice as an animal model limited our experiments to analyse the role of nc886 in immune function. Thus, in vivo, $1 \times 10^5$ cancer cells were injected into the left ventricle of C57BL/6 mice to investigate the differences between mimic and scramble cells in terms of immune rejection responses after 2 and 28 days. Histological analysis detected less immune rejection after mimic cell injection than after scramble cell injection. Inflammatory edema of the spleen, liver, lung, and bone occurred in the scramble group, especially splenomegaly, which lasted for 90 days; however, the nc886$^+$ group saw only slight inflammatory edema (Figure 3B; Figure S3). H&E staining showed that the spleens from the control groups were obviously necrotic, and splenic knots were lost compared with those from the nc886$^+$ groups. A large number of macrophages were recruited to necrotic or inflammatory regions in both groups. The nc886$^+$ group maintained intact splenic nodules (Figure 3A). The results suggested that compared with mimic cells, scramble cells caused a relatively intense organ inflammatory response associated with rejection, especially in the spleen (Figure 3). Clearly, nc886 might decrease the immune rejection response which is closely related to downregulation of MHCI expression in the nc886$^+$ cells.

3.4 | Macrophages recruited to the spleen exhibit positive expression of both CD68 and prostate-specific antigen (PSA)

The recruitment of innate immune cells to the spleen has been known to be important in the early-stage rejection reaction, so we focused on observing the micromorphological changes and characteristics of macrophages that were recruited to the splenic inflammatory region by transmission electron microscopy (TEM) and immunohistochemistry. Interestingly, the ultrastructures of macrophages in the scramble group and nc886$^+$ group were somewhat different from those in normal mice, for example, mitochondrial depolarization, swollen and extremely electron-dense mitochondria, and nucleolus loss in the scramble group (Figure 4A). CD68 is the most reliable marker of macrophages, and PSA is a specific marker of prostate cancer. Immunohistochemistry analysis of macrophages in the two groups indicated strong CD68 and PSA staining that persisted in areas of splenic inflammation for 28 days after 1E8 cell injection (Figure 4B). This result suggested that macrophages participated in immune rejection in the spleen.

**FIGURE 3** Nc886 alleviates the splenic inflammation induced by xenogeneic rejection in C57BL/C mice. A, Left panel, spleens from the two groups are shown at 28 days ($n = 5$). Right panel, the lengths of the spleens were calculated in the two groups. B, Representative H&E staining images (20× and 40×) of mouse spleen tissues from the scramble and nc886$^+$ groups at 2 and 28 days after injection of tumor cells into the left ventricle. The rectangles and triangles indicate the macrophages in the highlighted region. Scale bar, 50 μm and 20 μm.
3.5  |  **Nc886 might activate T cells or macrophages to destroy the tumor cells**

Furthermore, we investigated the distribution of tumor cells labeled with a GFP tag after left ventricle injection and the distribution of CD45^+F4/80^+GFP^+ macrophages through flow cytometric screening. GFP^+ cells in the nc886^+ group were significantly decreased compared with those in the scramble group (Figure 5A, left). At 2 and 28 days, the proportion of GFP^+ cells was highest in the spleen (52.7%), followed by the blood (49.7%), liver (7.4%), lung (0.7%), and bone (0.71%), in the scramble group and was highest in the blood (4.2%), followed by the spleen (3.6%), lung (2.9%), liver (2.2%), and bone (1.43%), in the nc886^+ group after 2 days. However, at 28 days, the highest proportions of GFP^+ cells were in the bone (0.99% and 0.91%, respectively) and spleen (1.46% and 0.71%, respectively) in the scramble and nc886^+ groups (Figure 5A, left). The highest proportion of CD45^+F4/80^+GFP^+ macrophages in total macrophages (CD45^+F4/80^+) was found in the spleen (85.6%), followed by liver (66.9%), the blood (65.7%), lung (65.7%), and bone (22.2%), in the scramble group and was found in the blood (60.6%), followed by the liver (51%), lung (23.8%), bone (22.9%), and spleen (14.1%), in the nc886^+ group at 2 days. After 28 days, CD45^+F4/80^+GFP^+ macrophages were also found in the bone (16.1% and 13.5%, respectively) and spleen (1.94% and 1.71%, respectively) in the scramble and mimic groups (Figure 5A, right). These data demonstrated a differential distribution of GFP^+ cells and CD45^+F4/80^+GFP^+ macrophages in the two groups at 2 or 28 days (Figure 5A). Furthermore, we identified aCD8^a^high population in the nc886^+ group that was not present in the scramble group in bone marrow aspirates but not in splenic homogenates; in contrast, CD206^high^ cells were found in both the bone marrow and spleen in the scramble group but not in the nc886^+ group. Additionally, aCD119^high^ (IFN-γ receptor) population was identified in the bone marrow and spleen in the nc886^+ group (Figure 5B). iNOS was not detected in either of the two groups (data not shown). The diagram explained that nc886 can promote the production of killer T cells (CD8a) due to its restriction for tumor antigen presentation. In addition, activated macrophages from bone marrow and spleen tissue between scramble and nc886^+ groups also exists differences in micromorphology and characteristics (Figure 5C).

3.6  |  **Nc886 decreases the M2-like macrophage population in vivo**

We noticed that there were many more GFP^+ BM-derived and splenic macrophages in the scramble group than in the nc886^+ group under a fluorescence microscope (Figure 6A). In combination with the TEM observations (Figure 4A), which showed that these macrophages in the spleen tissues of the scramble group had larger sizes and more abundant lysosomes and phagocytes than those in the nc886^+ group, these findings suggest that these macrophages that engulfed tumor cells should be one of the
causes of chronic inflammation. Using QRT-PCR, we found higher expression of CD163, IL-6, and IFN-Ƴ in the bone marrow of the nc886+ group than in the bone marrow of the scramble group; we also found lower expression of CD163 and IFN-Ƴ, but not IL-6, in spleen tissue homogenates from the nc886+ group than the respective levels in spleen tissue homogenates from the scramble group (Figure 6B, lower). The expression of CD206, IL-10, and TGF-β1 in the nc886+ group was significantly lower than that in the scramble group in both spleen tissue homogenates and bone marrow samples (Figure 6B, upper). These findings on M1 and M2 macrophages suggest that nc886 reduces...
the M2 macrophage population. What factors promote M2-like macrophage polarization in the scramble group?

### 3.7 TGF-β1 drives the process of M2 polarization in bone marrow and spleen

The growth of the splenic macrophages, not BM macrophages, in the two groups was significantly different, with the splenic macrophages in the nc886+ group proliferating faster than those in the scramble group (Figure 7A, left). We also found that scramble cells expressed higher levels of TGF-β1 than mimic cells (Figure 7A, middle). RAW264.7 grew more slowly cultured in the supernatant of scramble cells than of nc886+ cells (Figure 7A, right). Additionally, in vitro, 10 ng/mL TGF-β1 inhibited the growth of primary macrophages, either spleen- or BM-derived, in the two groups (Figure 7B), and inhibited the growth of the macrophage cell line RAW264.7 (Figure 7B, right). Considering the higher mRNA level of TGF-β1 in the BM samples and splenic homogenates of the scramble group (Figure 6B), we concluded that TGF-β1 slowed the growth of macrophages in the scramble group. Meanwhile, we hypothesize that TGF-β1 also induced an M2/M1 transition in our model. Indeed, after
treatment with 10 ng/mL TGF-β1, RAW264.7 cells rapidly began secreting IL-10, which lasted for 72 hours; however, CD206 or CD163 mRNA levels were increased shortly after 24 hours and then gradually decreased (Figure 7C, upper). Conversely, 10 ng/mL TGF-β1 continuously decreased IL-6 and TNF-α mRNA levels (Figure 7C, lower). These data suggest the vital role of TGF-β1 in the process of M2 polarization. The mechanical diagram is listed in Figure 8. It explains that nc886 reduces the M2 polarization of macrophages by reducing the expression of TGF-β1. TGF-β1 upsets the balance of M1/M2 transition by inhibiting the IL-6 and TNF-α secretion and promoting IL-10 release.

4 | DISCUSSION

Notably, our transcriptome sequencing data showed that nc886 downregulated the expression of HLA-A and
MAC et al.

Macrophages. In contrast, nc886 can activate M1-like phenotype, which are secreted by monocytes or IL-6 and TNF-α, and expression of IL-10 region. TGF-β1 increases the expression of CD8α+ T cells in the bone, but not in the spleen, were dramatically increased by 3.86-fold in the nc886+ group compared with that in the scramble group. These data support the idea that many mimic cells were attacked early by CD8+ T cells in the blood. Additionally, splenic rejection in the scramble group was more serious than that in the nc886+ group, lasting 90 days. Notably, splenic macrophages showed morphological changes by TEM between the two groups. The flow cytometry and QRT-PCR results suggest that many more M2 macrophages (pro-regenerative phenotype) were distributed in the bone and spleen of the scramble group than the number in the nc886+ group; however, many more M1 macrophages (pro-inflammatory) were found in the nc886+ group than in the scramble group. Macrophage polarization states often depend on a specific set of cytokines in the tissue microenvironment, including tumor necrosis factor (TNF) and TGF-β1. TGF-β1 is a well-documented factor that polarizes naïve macrophages to the M2 phenotype. In vitro, although TGF-β1 inhibited the growth of primary macrophages and RAW247.1 cells, it promoted CD206, CD163, and IL-10 upregulation in RAW247.1 cells and inhibited IL-6 and TNF-α expression. Surely, TGF-β1 is a vital factor in maintaining the M2-like phenotype of the scramble group. Interestingly, we did not find tumor colonies in important organs, such as the bone, lung, spleen, and liver, even after 120 days, so we believe that most tumor cells are ultimately eliminated by the host’s immune system. However, GFP+ or PSA-positive M2 macrophages still existed in the splenic inflammation region. This is an important reason for chronic inflammation in the spleen of the scramble group. These findings help us clarify why splenic inflammation in the scramble group is more serious than that in the nc886+ group.

However, why mimic cells with MHC I/II downregulation can still activate T cells and macrophages but scramble cells with MHC I overexpression cannot remain unknown. We postulate that some specific tumor antigens help them escape immune surveillance. Tumor cells, as a special type of APC, often process self-antigen peptides through the proteasome and endoplasmic reticulum system. Tumor antigens, such as differentiation antigens, mutational antigens, overexpressed cellular antigens, and viral antigens, contribute to immunological tolerance. However, our previous study showed that PSA levels did not differ between scramble cells and mimic cells. We found that the levels of CD274 (PD-L1), CD80, CD86, CD47, and DAMP molecules in scramble cells were not higher than those in mimic cells. Noteworthy, in our study model, scramble cells overexpressed TGF-β1 fivefold more than mimic cells, and high levels of TGF-β1 were also found in bone marrow aspirates and spleen homogenates from the scramble group. Accumulating evidence confirms that TGF-β1 is an important cause of immunosuppressive effectors in the scramble group. Certainly, some new tumor antigens need to be recognized in the future.

**FIGURE 8** The mechanical diagram in the process of M1/ M2 polarization. Our data support an important regulatory role of TGF-β1 in macrophage polarization. Scramble cells can secrete a high concentration of TGF-β1 to induce M2-like phenotype in inflammation region. TGF-β1 increases the expression of IL-10 and decreases the expression of IL-6 and TNF-α, which are secreted by monocytes or macrophages. In contrast, nc886 can activate M1-like phenotype through the mechanism of TGF-β1 inhibition.

*HLA-DRB* related to the endocytosis pathway. We subsequently tested the changes in some endoplasmic molecules associated with antigen processing. In accordance with our expectations, *nc886* reduced the expression of *TAP1*, *cathepsin* (early endoplasmic molecule), and *VTI1A* (late endoplasmic molecule) and increased *calnexin* mRNA levels. We additionally noticed that *nc886* could directly downregulate the expression level of *TAP1*, as validated by luciferase reporter and ChIP assays. Hence, it is postulated that *nc886* alters antigen processing and presentation by decreasing the expression of some HLA molecules and antigen transporters.

MHC I/II downregulation by *nc886* should be one of reasons to alleviate tumor cellular immunological rejection in immunocompetent mouse models. Considering that the homology of the HLA-A, HLA-B, and DRB1 genes between humans and mice is 64.36%, 68.61%, and 76.63%, respectively, the MHC mismatch-mediated host T cell response should not be neglected. In addition, the innate immune system is the fundamental protective barrier of our body against exogenous intrusion, especially macrophages, which are vital cells for xenogenic rejection. Our model showed a significant increase in macrophages and abnormal macrophage polarization in the spleen tissues of the scramble group.

We tracked the tissue distribution of bone-metastatic 1E8GFP+ cells entering host blood through flow cytometric analysis at 2 and 28 days. In both the scramble group and nc886+ group, 1E8GFP+ cells were mainly distributed in the blood and spleen at 2 days and in the bone and spleen at 28 days. However, the number of total 1E8GFP+ cells in the nc886+ group was dramatically less than that in the scramble group at 2 or 28 days, suggesting that more mimic cells than scramble cells were removed by immune-mediated destruction in the early stage. Further findings showed that the number of CD8α+ T cells in the bone, but not in the spleen, were dramatically increased by 3.86-fold in the nc886+ group compared with that in the scramble group. These data support the idea that many mimic cells were attacked early by CD8+ T cells in the blood. Additionally, splenic rejection in the scramble group was more serious than that in the nc886+ group, lasting 90 days. Notably, splenic macrophages showed morphological changes by TEM between the two groups. The flow cytometry and QRT-PCR results suggest that many more M2 macrophages (pro-regenerative phenotype) were distributed in the bone and spleen of the scramble group than the number in the nc886+ group; however, many more M1 macrophages (pro-inflammatory) were found in the nc886+ group than in the scramble group. Macrophage polarization states often depend on a specific set of cytokines in the tissue microenvironment, including tumor necrosis factor (TNF) and TGF-β1. TGF-β1 is a well-documented factor that polarizes naïve macrophages to the M2 phenotype. In vitro, although TGF-β1 inhibited the growth of primary macrophages and RAW247.1 cells, it promoted CD206, CD163, and IL-10 upregulation in RAW247.1 cells and inhibited IL-6 and TNF-α expression. Surely, TGF-β1 is a vital factor in maintaining the M2-like phenotype of the scramble group. Interestingly, we did not find tumor colonies in important organs, such as the bone, lung, spleen, and liver, even after 120 days, so we believe that most tumor cells are ultimately eliminated by the host’s immune system. However, GFP+ or PSA-positive M2 macrophages still existed in the splenic inflammation region. This is an important reason for chronic inflammation in the spleen of the scramble group. These findings help us clarify why splenic inflammation in the scramble group is more serious than that in the nc886+ group.
Many studies have reported that immunological tolerance is associated not only with tumor antigen mutations but also with low expression of MHC or TAP molecules. Nevertheless, with the notable exception of MHC I down-regulation, the opposite effect was observed in cancer in our model. We believe that nc886 affects tumor antigen loading and presentation on the surface of tumor cells by decreasing the protein levels of HLA-A and TAP1 transporters. TAPs mainly transport antigens from the cytoplasm into the endoplasmic reticulum for processing. We suggest a new point of view in which nc886 decreases the invasive ability of prostate cancer cells by altering tumor antigen processing and presentation.

ACKNOWLEDGMENTS
This work was supported by the National Nature Science Foundation of China (grant no. 81672834 and 81272406) and Scientific Research Common Program of Beijing Municipal Commission of Education (grant no. KM202010025004).

CONFLICT OF INTEREST
None declared.

AUTHOR CONTRIBUTIONS
Hui Ma, Ying Zhou, Jia-jie Yang, and Rong-Hui Yang performed the experiments, Miao Wang, Li-Yong Wang and Min-jie Wen analyzed the data, Lu Kong designed the experiments and prepared the manuscript and submitted the final manuscript.

DATA AVAILABILITY STATEMENT
The data used to support the findings of this study are available from the corresponding author upon request.

ORCID
Lu Kong https://orcid.org/0000-0002-4998-1327

REFERENCES
1. Silver MJ, Kessler NJ, Hennig BJ, et al. Independent genomewide screens identify the tumor suppressor VTRNA2-1 as a human epiallele responsive to periconceptional environment. Genome Biol. 2015;16:118.
2. Stadler PF, Chen JJ, Hackermüller J, et al. Evolution of vault RNAs. Mol Biol Evol. 2009;26:1975-1991.
3. Lee YS. A novel type of non-coding RNA, nc886, implicated in tumor sensing and suppression. Genomics & Informatics. 2015;13:26-30.
4. Fort RS, Matho C, Geraldo MV, et al. Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth. BMC Cancer. 2018;18:127.
5. Calderon BM, Conn GL. A human cellular noncoding RNA activates the antiviral protein 2′-5′-oligoadenylate synthetase I. J Biological Chemistry. 2018;293:16115-16124.
6. Golec E, Lind L, Qayyum M, Blom AM, King BC. The noncoding RNA nc886 regulates PKR signaling and cytokine production in human cells. J Immunol. 2019;202:131-141.
7. Lei ZG, Ren XH, Wang SS, Liang XH, Tang YL. Immunocompromised and immunocompetent mouse models for head and neck squamous cell carcinoma. OncoTargets Therapy. 2016;9:545-555.
8. Caldwell A, Siddle HV. The role of MHC genes in contagious cancer: the story of Tasmanian devils. Immunogenetics. 2017;69:537-545.
9. Reichart B, Guethoff S, Brenner P, et al. Xenotransplantation of cells, tissues, organs and the german research foundation transregio collaborative research centre 127. Adv Exp Med Biol. 2015;865:143-155.
10. Neefjes J, Jongsmra ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11:823-836.
11. Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. DAMP-induced allograft and tumor rejection: the circle is closing. American J Transplant. 2016;16:3322-3337.
12. Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. Transplantation and Damage-Associated Molecular Patterns (DAMPs). American J Transplant. 2016;16:3338-3361.
13. Ochando J, Ordikhani F, Boros P, Jordan S. The innate immune response to allografts: mechanisms and therapeutic potentials. Cell Mol Immunol. 2019;16:350-356.
14. Noguchi Y, Maeda A, Lo PC, et al. Human TIGIT on porcine aortic endothelial cells suppresses xenogeneic macrophage-mediated cytotoxicity. Immunobiology. 2019;224:605-613.
15. Mills CD. Anatomy of a discovery: m1 and m2 macrophages. Front Immunol. 2015;6:212.
16. Sang Y, Brichallii W, Rowland RR, Blecha F. Genome-wide analysis of antiviral signature genes in porcine macrophages at different activation statuses. PLoS One. 2014;9:e87613.
17. Menen RS, Hassanein MK, Momiyama M, et al. Tumor-educated macrophages promote tumor growth and peritoneal metastasis in an orthotopic nude mouse model of human pancreatic cancer. In Vivo. 2012;26:565-569.
18. Zhuang G, Meng C, Guo X, et al. A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. Circulation. 2012;125:2892-2903.
19. Kazansky DB. MHC restriction and allogeneic immune responses. J Immunotoxicol. 2008;5:369-384.
20. Parmar S, Del Lima M, Zou Y, et al. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood. 2009;114:2884-2887.
21. Land WG, Guttmann T, Daar AS. Emerging science, emerging ethical issues: who should fund innate alloimmunity-suppressing drugs? Acta Chir Belg. 2008;108:73-82.
22. Zaza G, Leventhal J, Signorini L, Gambaro G, Cravedi P. Effects of antirejection drugs on innate immune cells after kidney transplantation: miR-223 in obesity-associated adipose tissue inflammation. J Immunology. 2019;10:2978.
23. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol. 2008;9:558-566.
24. Yoon TY, Munson M. SNARE complex assembly and disassembly. Front Immunol. 2016;7:397-R401.
25. Hoornaert CJ, Le Blon D, Quarta A, et al. Concise review: innate and adaptive immune recognition of allogeneic and xenogeneic cell
transplants in the central nervous system. *Stem Cells Transl Med.* 2017;6:1434-1441.

26. Cunha C, Gomes C, Vaz AR, Brites D. Exploring new inflammatory biomarkers and pathways during LPS-induced M1 polarization. *Mediators Inflamm.* 2016;2016:6986175.

27. Zhang S, Liu Y, Zhang X, et al. Prostaglandin E2 hydrogel improves cutaneous wound healing via M2 macrophages polarization. *Theranostics.* 2018;8:5348-5361.

28. Murray LA, Chen Q, Kramer MS, et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. *International J Biochemistry Cell Biology.* 2011;43:154-162.

29. Reed RC, Nicchitta CV. Chaperone-mediated cross-priming: a hitchhiker’s guide to vesicle transport (review). *Int J Mol Med.* 2000;6:259-264.

30. Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. *Ann N Y Acad Sci.* 2013;1284:1-5.

31. Elliott JM, Yokoyama WM. Unifying concepts of MHC-dependent natural killer cell education. *Trends Immunol.* 2011;32:364-372.

32. Ochsenbein AF, Sierra S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. *Nature.* 2001;411:1058-1064.

33. De Visser KE, Schumacher TN, Kruisbeek AM. CD8+ T cell tolerance and cancer immunotherapy. *J Immunother.* 2003;26:1-11.

34. Leclerc M, Mezquita L, Guillebot De Nerville G, et al. Recent advances in lung cancer immunotherapy: input of T-cell epitopes associated with impaired peptide processing. *Frontiers Immunol.* 2019;10:1505.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Ma H, Wang M, Zhou Y, et al. *Noncoding RNA 886 alleviates tumor cellular immunological rejection in host C57BL/6 mice.* *Cancer Med.* 2020;9:5258–5271. [https://doi.org/10.1002/cam4.3148](https://doi.org/10.1002/cam4.3148)